For decades, patients diagnosed with dry age-related macular degeneration (AMD) have often faced a frustrating and discouraging reality: there were very limited treatment options available. Unlike wet macular degeneration, which can often be treated with injections, dry AMD — which accounts for approximately 90% of all AMD cases — historically offered little beyond observation, monitoring, nutritional supplements, and lifestyle recommendations. Many patients were told to simply “watch and wait” as their central vision slowly declined over time. Today, however, that reality is beginning to change dramatically.

A groundbreaking FDA-authorized technology known as Photobiomodulation (PBM) therapy is bringing new hope to patients living with dry AMD. Delivered through the Valeda Light Delivery System, PBM therapy represents one of the most exciting innovations in retina care in many years. For the first time, patients with dry AMD may now have access to a treatment shown in clinical studies to improve visual function and potentially slow disease progression.

Photobiomodulation works by using specific wavelengths of light to stimulate retinal cells and improve cellular function deep within the retina. Scientific research has shown that PBM may enhance mitochondrial activity, reduce inflammation, improve blood flow, and decrease oxidative stress — all factors believed to contribute to the progression of macular degeneration. By improving the health and metabolism of retinal cells, PBM helps support the retina’s ability to function more effectively.

The FDA authorization of the Valeda system followed extensive scientific investigation and multiple clinical trials. The landmark LIGHTSITE studies generated tremendous excitement among retina specialists and ophthalmologists worldwide. In these studies, patients treated with PBM demonstrated measurable improvements in visual acuity, contrast sensitivity, and overall retinal function compared to untreated patients. Many patients gained letters on standardized vision testing, and some maintained these improvements over extended follow-up periods. Researchers also observed signs suggesting slower progression of retinal damage in treated eyes.

For patients who have spent years hearing that “nothing can be done” for dry AMD, these findings are incredibly meaningful. PBM therapy is changing the conversation surrounding dry macular degeneration and offering patients genuine optimism for the future.

One of the most remarkable aspects of PBM therapy is its excellent safety profile. The treatment is completely non-invasive, painless, and comfortable. There are no injections into the eye, no surgery, no needles, and no recovery time. Patients simply sit comfortably during a series of light therapy sessions that take only minutes to perform. Clinical studies have demonstrated virtually no significant side effects or safety concerns associated with treatment. This makes PBM one of the safest and most patient-friendly technologies currently available in retinal care.

Patients often ask who may qualify for treatment. In general, the best candidates are individuals with early to intermediate dry AMD who are beginning to experience symptoms such as blurry central vision, difficulty reading, trouble driving at night, decreased contrast sensitivity, or distortion in vision. Patients with drusen deposits or non-central geographic atrophy may particularly benefit from evaluation. Determining candidacy requires a comprehensive retinal examination and advanced retinal imaging performed by an experienced eye specialist.

Milford Franklin Eye Center is proud to be among the very first centers in Massachusetts — and among the earliest centers in the United States — to offer this revolutionary FDA-authorized technology. In fact, MFEC is the fourth center in Massachusetts to acquire the Valeda PBM system. Remarkably, many major hospitals and eye centers in Boston still do not yet offer this breakthrough treatment. Milford Franklin Eye Center has always remained committed to bringing the most advanced and innovative technologies directly to the communities we serve so patients can receive world-class care closer to home.

This commitment to innovation reflects the core mission of MFEC: providing exceptional eye care using the latest advancements in medicine while maintaining the personalized attention and compassion of a community-based practice. Our goal has always been to empower local patients with access to the same cutting-edge technology available at leading centers across the country, without requiring long-distance travel for specialized care.

Patients diagnosed with dry AMD are strongly encouraged to contact our office for an evaluation, consultation, or second opinion regarding PBM therapy. Many optometrists and ophthalmologists may not yet offer this technology or may not yet be familiar with the newest treatment advances available for dry macular degeneration. PBM therapy represents a true revolution in eye care because it offers something patients with dry AMD have rarely had before: hope for preserving — and in some cases improving — vision.

Milford Franklin Eye Center is also proud to provide on-site retina specialty care through Dr. Alyse Richard, a highly trained retina specialist dedicated to the diagnosis and treatment of retinal diseases including dry and wet macular degeneration, diabetic retinopathy, retinal vascular disease, retinal tears, and other complex retinal conditions. Dr. Richard combines advanced subspecialty expertise with compassionate, patient-centered care and is committed to helping patients preserve their vision using the latest evidence-based treatments available today.

If you or a loved one has been diagnosed with dry AMD, now is the time to learn more about this exciting breakthrough. Early evaluation and treatment may make a meaningful difference in preserving vision, maintaining independence, and improving quality of life. Time equals vision. Patients are encouraged to contact Milford Franklin Eye Center for immediate appointments and second opinions regarding this revolutionary new technology that is changing the future of dry macular degeneration care.

For more details, see our ad on the previous page.

Sponsored articles are submitted by our advertisers. The advertiser is solely responsible for the content of this article.